Insider Transactions in Q2 2024 at G1 Therapeutics, Inc. (GTHX)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 13
2024
|
Jacks Lee |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+33.33%
|
-
|
|
Jun 13
2024
|
Glenn P Muir |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+4.64%
|
-
|
|
Jun 13
2024
|
Alicia Secor |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+25.0%
|
-
|
|
Jun 13
2024
|
Norman Sharpless |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+33.33%
|
-
|
|
Jun 13
2024
|
Garry A Nicholson |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+22.53%
|
-
|
|
Jun 13
2024
|
Cynthia Schwalm |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+21.79%
|
-
|
|
May 23
2024
|
Monica R. Thomas Chief Legal & People Officer |
SELL
Open market or private sale
|
Direct |
5,826
-5.04%
|
$23,304
$4.27 P/Share
|
|
May 13
2024
|
Andrew Perry Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
8,151
-9.36%
|
$32,604
$4.79 P/Share
|
|
May 13
2024
|
Terry L Murdock Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
8,151
-7.86%
|
$32,604
$4.79 P/Share
|
|
May 13
2024
|
John V. Umstead Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,151
-5.05%
|
$32,604
$4.79 P/Share
|
|
May 13
2024
|
Mark Avagliano Chief Business Officer |
SELL
Open market or private sale
|
Direct |
8,151
-3.74%
|
$32,604
$4.79 P/Share
|
|
May 13
2024
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,151
-4.8%
|
$32,604
$4.79 P/Share
|
|
May 13
2024
|
John E. (Jack) Bailey Jr. President and CEO |
SELL
Open market or private sale
|
Direct |
37,258
-7.61%
|
$149,032
$4.79 P/Share
|